News

Conference Coverage

Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma

05/28/2024

Allison Casey ;

According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...

According to a phase 2 trial...

05/28/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

Conference Coverage

Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma

01/20/2024

Stephanie Holland ;

Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...

Results from a phase 2 study...

01/20/2024

Oncology

Conference Coverage

Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma

01/19/2024

Allison Casey ;

According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.

According to results from a...

01/19/2024

Oncology

Conference Coverage

Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer

01/19/2024

Janelle Bradley ;

First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...

First-line treatment with...

01/19/2024

Oncology

News

Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer

11/02/2023

Allison Casey ;

On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.

On November 1, 2023, the FDA...

11/02/2023

Oncology

Monica Niger, MD, National Cancer Institute - MIlan

Videos

Clinical Relevance of BRAF Alterations in Biliary Tract Cancers

08/22/2023

Monica Niger , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Monica Niger, MD, discusses the clinical relevance and actionability of BRAF alterations among patients with advanced biliary tract cancers.

At the 2023 World Congress on...

08/22/2023

Oncology

Leony Antoun, MD, Gustave Roussy Cancer Campus

Videos

Effect of Molecular Profiling on Survival Among Patients With Biliary Tract Cancers

08/09/2023

L. Antoun ;

At the 2023 World Congress on Gastrointestinal Cancers, Leony Antoun, MD, discusses the impact of molecular profiling on survival among patients with advanced biliary tract cancers.

At the 2023 World Congress on...

08/09/2023

Oncology

News

Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer

07/20/2023

Allison Casey ;

In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.

In a phase 2b study, zanidatamab...

07/20/2023

Oncology

James Harding, MD, Memorial Sloan Kettering Cancer Center

Videos

Novel Dual IDH-Inhibitor Plus Chemotherapy Showed Promising Efficacy, Safety for Patients With Advanced IDH-Mutant Cholangiocarcinoma

07/12/2023

J. Harding ;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, the IDH1/2-inhibitor LY3410738 showed promising efficacy and safety in combination with chemotherapy for patients with locally advanced or metastatic...

According to a study presented...

07/12/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology